series-a
Stage
1
Investors
About
Chameleon Biosciences engineers next-generation adeno-associated virus (AAV) vectors designed to reduce immune response, enabling repeated dosing and improving efficacy for gene replacement and editing therapies targeting conditions such as hemophilia and Niemann-Pick Type C.
Explore Chameleon Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.